Y-Mabs Therapeutics Operating Income

As of the most recent data (June 2025), YMAB shows a operating income of $-27M. That compares with $-28M in the prior-year period — up 3.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YMAB's operating income is now $-27M (was $-28M) — a 3.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Y-Mabs Therapeutics is outperforming or lagging.

Tracking YMAB's operating income over time shows whether Y-Mabs Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-27M That compares with $-28M in the prior-year period — up 3.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Y-Mabs Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-27M) with ownership activity and broader fundamentals.

Y-Mabs Therapeutics's operating income is $-27M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.